Influence of Androgens on Circulating Adiponectin in Male and Female Rodents

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Yarrow, Joshua F ^a,b   Beggs, Luke A ^a,b   Conover, Christine F ^a   McCoy, Sean C ^a   Beck, Darren T ^a   Borst, Stephen E ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ESTRADIOL; TESTOSTERONE; TESTOSTERONE ENANTATE; TRENBOLONE;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GONADECTOMY; HORMONE ACTION; INTRAABDOMINAL FAT; MALE; MOLECULAR WEIGHT; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RODENT; TESTOSTERONE BLOOD LEVEL; WESTERN BLOTTING;

ADIPONECTIN; ANIMALS; FEMALE; MALE; PLACEBOS; RATS; RATS, INBRED F344; SEX FACTORS; TESTOSTERONE; TRENBOLONE ACETATE;

EID: 84867346127     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047315     Document Type: Article

References (58)

1. Swarbrick MM, Havel PJ, (2008) Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6: 87-102.
2. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, et al. (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87: 5662-5667.
3. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, et al. (2003) Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 88: 4823-4831.
4. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152-12162.
5. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, et al. (2003) Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52: 268-276.
6. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, et al. (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280: 18073-18080.
7. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, et al. (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51: 2734-2741.
8. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, et al. (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46: 459-469.
9. Laughlin GA, Barrett-Connor E, May S, (2007) Sex-specific determinants of serum adiponectin in older adults: the role of endogenous sex hormones. Int J Obes (Lond) 31: 457-465.
10. Yarrow JF, McCoy SC, Borst SE (2011) Intracrine and Myotrophic Roles of 5a Reductase and Androgens: A Review. Med Sci Sports Exerc: Epub Ahead of Print.
11. Bhasin S, Taylor WE, Singh R, Artaza J, Sinha-Hikim I, et al. (2003) The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 58: M1103-1110.
12. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S, (2003) Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144: 5081-5088.
13. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E, (2004) Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 60: 500-507.
14. Yanase T, Fan W, Kyoya K, Min L, Takayanagi R, et al. (2008) Androgens and metabolic syndrome: lessons from androgen receptor knock out (ARKO) mice. J Steroid Biochem Mol Biol 109: 254-257.
15. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, et al. (2001) Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281: E1172-1181.
16. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, et al. (2005) Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90: 678-688.
17. Frederiksen L, Hojlund K, Hougaard DM, Mosbech TH, Larsen R, et al. (2011) Testosterone therapy decreased subcutaneous fat and adiponectin in ageing men. Eur J Endocrinol.
18. Page ST, Herbst KL, Amory JK, Coviello AD, Anawalt BD, et al. (2005) Testosterone administration suppresses adiponectin levels in men. J Androl 26: 85-92.
19. Belanger C, Luu-The V, Dupont P, Tchernof A, (2002) Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res 34: 737-745.
20. Luu-The V, Labrie F, (2010) The intracrine sex steroid biosynthesis pathways. Prog Brain Res 181: 177-192.
21. MacKenzie SM, Huda SS, Sattar N, Fraser R, Connell JM, et al. (2008) Depot-specific steroidogenic gene transcription in human adipose tissue. Clin Endocrinol (Oxf) 69: 848-854.
22. Kafkas S, Dost T, Ozkayran H, Yenisey C, Tuncyurek P, et al. (2011) Effect of estrogen therapy on adipocytokines in ovariectomized-aged rats. J Obstet Gynaecol Res.
23. Kunnari A, Santaniemi M, Jokela M, Karjalainen AH, Heikkinen J, et al. (2008) Estrogen replacement therapy decreases plasma adiponectin but not resistin in postmenopausal women. Metabolism 57: 1509-1515.
24. Matyskova R, Zelezna B, Maixnerova J, Koutova D, Haluzik M, et al. (2010) Estradiol supplementation helps overcome central leptin resistance of ovariectomized mice on a high fat diet. Horm Metab Res 42: 182-186.
25. Christodoulakos GE, Lambrinoudaki IV, Creatsa MG, Economou EV, Siasou Z, et al. (2008) Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. Climacteric 11: 155-165.
26. Pfaehler A, Nanjappa MK, Coleman ES, Mansour M, Wanders D, et al. (2011) Regulation of adiponectin secretion by soy isoflavones has implication for endocrine function of the testis. Toxicol Lett.
27. Leung KC, Xu A, Craig ME, Martin A, Lam KS, et al. (2009) Adiponectin isoform distribution in women-relationship to female sex steroids and insulin sensitivity. Metabolism 58: 239-245.
28. Merki-Feld GS, Imthurn B, Rosselli M, Spanaus K, (2011) Serum concentrations of high-molecular weight adiponectin and their association with sex steroids in premenopausal women. Metabolism 60: 180-185.
29. Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L, (2006) Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol 155: 453-460.
30. Lapauw B, TSjoen G, Mahmoud A, Kaufman JM, Ruige JB, (2009) Short-term aromatase inhibition: effects on glucose metabolism and serum leptin levels in young and elderly men. Eur J Endocrinol 160: 397-402.
31. Yarrow JF, Conover CF, Purandare AV, Bhakta AM, Zheng N, et al. (2008) Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats. Am J Physiol Endocrinol Metab 295: E1213-1222.
32. Yarrow JF, Conover CF, McCoy SC, Lipinska JA, Santillana CA, et al. (2011) 17beta-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate. Am J Physiol Endocrinol Metab 300: E650-660.
33. McCoy SC, Yarrow JF, Conover CF, Borsa PA, Tillman MD, et al. (2012) 17beta-Hydroxyestra-4,9,11-trien-3-one (Trenbolone) preserves bone mineral density in skeletally mature orchiectomized rats without prostate enlargement. Bone 51: 667-673.
34. Berra M, Armillotta F, D'Emidio L, Costantino A, Martorana G, et al. (2006) Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl 8: 725-729.
35. Traish AM, Saad F, Guay A, (2009) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30: 23-32.
36. Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, et al. (2010) The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab 95: 3955-3964.
37. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I, (2002) Estradiol in elderly men. Aging Male 5: 98-102.
38. Bauer ER, Daxenberger A, Petri T, Sauerwein H, Meyer HH, (2000) Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. APMIS 108: 838-846.
39. Yarrow JF, McCoy SC, Borst SE, (2010) Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids 75: 377-389.
40. Le Guevel R, Pakdel F, (2001) Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods. Hum Reprod 16: 1030-1036.
41. Borst SE, Conover CF, (2006) Orchiectomized Fischer 344 male rat models body composition in hypogonadal state. Life Sci 79: 411-415.
42. Tan RS, Salazar JA, (2004) Risks of testosterone replacement therapy in ageing men. Expert Opin Drug Saf 3: 599-606.
43. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, et al. (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63: 280-293.
44. Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, Acha AA, Ostir GV, (2006) Androgen treatment and muscle strength in elderly men: A meta-analysis. J Am Geriatr Soc 54: 1666-1673.
45. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M, (2011) Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 25: 337-353.
46. Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, et al. (2007) Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82: 20-28.
47. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, et al. (2005) Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 63: 381-394.
48. Jain P, Rademaker AW, McVary KT, (2000) Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 164: 371-375.
49. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, et al. (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335: 1-7.
50. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, et al. (2003) Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 88: 1478-1485.
51. Storer TW, Woodhouse L, Magliano L, Singh AB, Dzekov C, et al. (2008) Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc 56: 1991-1999.
52. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, et al. (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60: 1451-1457.
53. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, et al. (2010) Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95: 2560-2575.
54. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, et al. (2010) Adverse events associated with testosterone administration. N Engl J Med 363: 109-122.
55. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, et al. (2007) Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82: 29-39.
56. Heufelder AE, Saad F, Bunck MC, Gooren L, (2009) Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30: 726-733.
57. Cornoldi A, Caminiti G, Marazzi G, Vitale C, Patrizi R, et al. (2010) Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol 142: 50-55.
58. Kapoor D, Goodwin E, Channer KS, Jones TH, (2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154: 899-906.